Address: Kar Plaza Kayışdağı Cad. Karaman
Çiftlik Yolu No:47 E Blok Kat:3
34752 İçerenköy / Kadiköy – İstanbul
Tel: +90 216 5776505
Web: http://www.daiichi-sankyo.com.tr/
As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. (DSI) draws on a rich heritage of innovation, integrity and accountability. While the success of our medicines speaks for itself, our corporate mission defines our vision and purpose.
To enrich the quality of life around the world through the development of innovative pharmaceuticals.
How do we bring this corporate mission to life? By bringing together medical and scientific expertise, a collaborative and ethical culture, and a robust pipeline. At Daiichi Sankyo, innovation is more than a corporate motto. It’s a philosophy we put into practice each and every day.
Together with our healthcare partners, Daiichi Sankyo is helping patients live healthier lives. Our
comprehensive portfolio offers a wide range of treatments for patients in a number of disease
categories including hypertension, heart disease, diabetes and hyperlipidemia/atherosclerosis.
From the discovery of epinephrine (also known as adrenaline) in 1889, to the development of the statin class of lipid-lowering agents and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes, our history of innovation continues to define our vision and purpose. With our scientific curiosity, willingness to examine new ideas and pairing of existing information with novel concepts, we create medicines as well as new methods of drug discovery and delivery.
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in…
Ismail Yormaz, vice president & regional director south-east at Recordati, shares the management secrets that have helped him grow Recordati into one of the top pharma companies in Turkey. He…
Sule Mene, co-founder, president and CEO of Mene Health Group, shares with PharmaBoardroom the journey of her company starting as the first government-approved CRO of Turkey, its parallel growth alongside…
Tuğçe Koç reveals how Onko Koçsel was able to quickly grow from an in-licenser to a production-oriented pharmaceutical company with an international reach. She also offers her take on how…
Kazim Dinç, chairman of the board of SURDER and former Minister of Health of Turkey, offers his insights into the Turkish OTC and health products market, highlighting the challenges facing…
Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and…
Acibadem’s Mehmet Ali Aydınlar offers his insights into the Turkish healthcare sector, highlighting Turkey’s burgeoning healthcare tourism industry. He also describes Acıbadem’s focus of growth, globalization and fundamental values that…
Murat Kavrar, country manager at Ekol Turkey, offers readers a look at Ekol’s innovative approach to the logistics sector, emphasizing his company’s R&D capacity and eco-friendly solutions that provide client…
With the construction of state-of-the-art public and private hospitals, Turkey is poised to become a global leader in medical tourism. Turkey has always been a popular tourist destination, given…
Abidin Gulmus, founder and chairman of Gen Ilaç, describes the company’s impressive journey to become Turkey’s principle orphan drug distributor and shares his vision for leveraging the company’s domestic expertise…
In 2016 the Turkish Medicine and Medical Devices Agency (TiTCK) implemented a localisation policy to reduce Turkey’s reliance on imports – a few years later, it has created a young,…
Massimo d’Eufemia, head representative of the European Investment Bank (EIB) in Turkey, highlights the importance of Turkey for the EIB and how the country’s geographic position and key economic role…
Tahsin Yüksel, general manager of Teva Turkey, analyzes the strategic importance of pharmaceutical branding in Turkey, shares the story of Teva’s adaptation to the unique market needs, and offers his…
See our Cookie Privacy Policy Here
